Down 13% from Oct 30 to Nov 10.
HRMY's Quality Score fell 1 point on Tue, Nov 10, to 4. Its down days drew more trading than its up days lately (3 chart checks stopped).
Follow HRMY's trial news. Pro members can get an alert when Harmony Biosciences Holdings files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2022 high | Down 45% |
| Latest filing | 8-K, Nov 4 |
Harmony Biosciences Stock Dives As CEO Jeffrey Dayno Plans His Exit
HRMY closed −5.1% that day.
After its last 4 reports it closed +0.7% on average, higher 2 of 4 times.
Chief Medical Officer Kumar Budur sold 38,452 shares on Sep 18. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
HRMY is #84 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 84 |
Expected to report Tue Feb 23, before the open (in 105 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $0.81 a share, from $0.87.
“The increase in cost of product sold as a percentage of net product revenue was primarily driven by new royalties related to the Novitium license agreement.”
HRMY's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| WAKIX net revenue | $1.00B to $1.04B |
“The decline in earnings was primarily driven by an increase in milestone charges and the new MSN royalty charges during the third quarter of 2026 as compared to the same quarter in 2025.”
From its results filing (SEC filing · Nov 4)
Sales grew 40% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 1.4% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -6.8% | -7.0% | -9.4% |
| Aug 4, 2026 | +4.2% | +8.9% | +9.6% |
| May 7, 2026 | -11.7% | -4.2% | -6.0% |
Sales grew every year from 2019 to 2025, to $868M. It made a profit in five of the seven years.
RSI 34.1, MACD below signal, below both averages. Not scored.
One insider sold $3.1M across 7 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: HRMY is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
“Our industry is highly competitive and subject to rapid and significant change as research provides a deeper understanding of rare neurological disorders, including narcolepsy, and as new therapies are developed.”
HRMY scores 4 today, which Breakaway calls Below Average. It is #84 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 13% from Oct 30 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
HRMY scores 4 today, which Breakaway calls Below Average (0 to 5). That is #84 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind HRMY's 4.
One insider sold $3.1M across 7 filings in the last 6 months. No open-market buys on record. The newest is Kumar Budur, Chief Medical Officer, who sold $1.5M on Sep 18. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.